GlassScriptPhysician profile
Nereida A Parada
NPI 1376636175
$10,491.76
in general payments reported to CMS, 2019-2025
23 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $96.08 · 2021: $498 · 2022: $456 · 2023: $6,062 · 2024: $1,077 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,208 · Food and Beverage: $4,207 · Travel and Lodging: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,208.00 |
| Food and Beverage | $4,207.12 |
| Travel and Lodging | $376.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,900.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,301.42 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,044.53 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $611.43 | 2023-2025 | Dupixent |
| Philips North America LLC | $571.36 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Astrazeneca Uk Limited | $145.53 | 2023-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.43 | 2023 | Ofev |
| Mylan Specialty L.P. | $110.06 | 2023-2024 | Yupelri, Tobi Podhaler |
| Amgen INC. | $103.58 | 2023-2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $97.25 | 2024-2025 | Prolastin-C Liquid |
| Insmed, INC. | $92.72 | 2024-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $66.08 | 2020 | |
| Genentech USA, INC. | $54.89 | 2023 | Xolair, Actemra |
| Viatris Specialty LLC | $40.00 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $39.73 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $30.00 | 2020 | |
| Ucb, INC. | $23.05 | 2023 | Cimzia |
| United Therapeutics Corporation | $22.29 | 2023 | |
| Electromed, INC. | $22.04 | 2022 | |
| Merck Sharp & Dohme LLC | $21.29 | 2024 | Zerbaxa |
| Alcresta Therapeutics, INC. | $20.73 | 2025 | Relizorb |
| Abbvie INC. | $16.62 | 2025 | |
| Gilead Sciences, INC. | $16.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nereida Parada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.